Therapeutic Development Pipeline
Sales of Macrilen® (macimorelin) are temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency ("AGHD"), until anticipated re-launch with an alternate commercialization partner. Aeterna has an ongoing effort to identify strategic development and commercialization partner.
Specialty Biopharmaceutical Company
Data delayed 15 minutes unless otherwise indicated